Efficacy of once-weekly dulaglutide on HbA1c reduction in East Asian patients with T2DM: subgroup analysis according to potential influencing factors

被引：0
|
作者：
Peng, Yongde [1 ]
Zhang, Bin [2 ]
Hou, Jianing [2 ]
机构：
[1] Shanghai First Peoples Hosp, Shanghai, Peoples R China
[2] Lilly Suzhou Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
DIABETES-METABOLISM RESEARCH AND REVIEWS | 2019年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1524615
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Modelling HbA1c Trajectory in Patients with Type 2 Diabetes Mellitus (T2DM)
    Mcewan, Phil
    Fellows, Jonathan
    Yapp, Rhiannon
    Bergenheim, Klas
    Qin, Lei
    Varol, Nebibe
    Bennett, Hayley
    Gordon, Jason
    DIABETES, 2016, 65 : A322 - A322
  • [22] Treatment Progression and Impact of HbA1C in Type 2 Diabetes (T2DM) Patients
    Dibello, Julia R.
    Levy, Brian
    Mehra, Maneesha
    DIABETES, 2010, 59 : A623 - A624
  • [23] The potential value of establishing a standard HbA1c value for the prevention of cognitive impairment in T2DM patients
    Zhen, Yanfeng
    Fang, Hui
    Liu, Xingyu
    Xu, Gang
    Tian, Jinli
    Li, Yukai
    Zhang, Cuilin
    Zhou, Li
    Yang, Yue
    Sun, Xueling
    Zhang, Guyue
    Zhang, He
    Xu, Jing
    Zhou, Lei
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2015, 31 : 70 - 70
  • [24] Subgroup analysis of Phase 3 study of dapagliflozin, glimepiride and metformin ER FDC in T2DM patients with HbA1c 9%-11%
    Sahay, R.
    Gangwani, D.
    Singh, M.
    Gupta, S.
    Rajurkar, M.
    Saha, S.
    Patil, D.
    Ghadge, P.
    Lakhwani, L.
    Mehta, S.
    Joglekar, S.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
  • [25] Factors Associated with A1c Reduction in Asian Patients with T2DM: An Analysis of the FINE Asia Registry
    Ji, Linong
    Wang, Edward
    Tsai, Shih-Tzer
    DIABETES, 2011, 60 : A607 - A607
  • [26] Real-World Impact of HbA1c Reduction on Treatment Intensification and HbA1c Goal Attainment in T2DM Patients Initiated on SGLT2i
    Brunton, Stephen
    Rozjabek, Heather M.
    Pilon, Dominic
    Lafeuille, Marie-Helene
    Kamstra, Rhiannon L.
    Wynant, Willy
    Bookhart, Brahim
    Lefebvre, Patrick
    DIABETES, 2018, 67
  • [27] Exploration of the Relationship of Reduction in HbA1c and Body Weight by Dapagliflozin in Patients With T2DM: Pooled Analysis of 5 Clinical Trials
    Hardy, Elise
    Salsali, Afshin
    Wessman, Catrin
    Wei, Li
    Mansfield, Traci
    Parikh, Shamik
    DIABETES, 2012, 61 : A252 - A252
  • [28] Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs. 1.0 mg by Baseline HbA1c and BMI: SUSTAIN FORTE Subgroup Analyses
    Buse, John B.
    Auerbach, Pernille
    Bajaj, Harpreet S.
    Fukushima, Yasushi
    Lingvay, Ildiko
    Macura, Stanislava
    Sondergaard, Anette L.
    Tankova, Tsvetalina
    Tentolouris, Nikolaos
    Frias, Juan P.
    DIABETES, 2021, 70
  • [29] Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10
    Matthew Capehorn
    Yasmin Ghani
    Charlotte Hindsberger
    Pierre Johansen
    Esteban Jódar
    Diabetes Therapy, 2020, 11 : 1061 - 1075
  • [30] A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
    Johansen, Pierre
    Hunt, Barnaby
    Iyer, Neeraj N.
    Tam Dang-Tan
    Pollock, Richard F.
    ADVANCES IN THERAPY, 2019, 36 (05) : 1190 - 1199
12345